Drug Combination Details
| General Information of the Combination (ID: C34583) | |||||
|---|---|---|---|---|---|
| Name | Celastrol NP Info | + | Gefitinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | EGFR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | STAT3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
| In-vivo Model | Each mouse (five-week-old BALB/c nude mice) was subcutaneously injected with 2 * 106 H1975 lung carcinoma cells in logarithmic growth phase. | |||||
| Experimental
Result(s) |
Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance. Anticancer Drugs. 2018 Sep;29(8):748-755. | |||
